Jules Griffin
Jules Griffin holds a joint appointment between the UK Medical Research Council Human Nutrition Research and the University of Cambridge. He is also an Honorary Professor at Imperial College London (2012-2015) and was a visiting professor at the University of Cagliari, Sardinia, Italy (2011-2012). The programme of research focuses on the development of metabolomics and lipidomics tools to investigate aspects of the Metabolic Syndrome. In particular his team has an interest in identifying biomarkers that stratify patients according to risk factor of the Metabolic Syndrome and understand the associated underlying mechanisms.

From mice to man and back again: applications of metabolomics to understand type 2 diabetes and obesity
(Marica Hall, June 24th, 09:30)
There is a global epidemic in terms of the rise in the number of sufferers with type 2 diabetes (T2DM) with the world health organisation estimating currently 347 million people worldwide with diabetes and the disease representing the 7th largest cause of death globally. While a number of genes have been identified that play a role in the development of T2DM, most are associated with rare monozygotic forms of the disease, and do not model the complex interactions between genotype and the environment, and in particular diet and exercise, that is responsible for the development of T2DM in many human cases. We have been using a combination of high resolution mass spectrometry and NMR spectroscopy as tools to model the interactions between diet, age and genetic susceptibility in mouse models of T2DM. Both diet and age accelerate the development of T2DM in the obob mouse, recapitulating many of the features occurring in human disease. To translate the metabolomics results into clinical applications we have also cross compared our mouse studies with human patients possessing different forms of T2DM. In terms of both metabolomics and lipidomic perturbations both mouse models and human sufferers of T2DM showed a high degree of similarity. This has allowed us to return to the animal models and investigate tissue specific mechanisms using metabolomics, transcriptomics and proteomics that are responsible for specific metabolite changes. This translational systems medicine approach should allow us to define new biomarkers of various aspects of T2DM and identify the underlying mechanisms that they represent.
Department of Biochemistry and MRC Human Nutrition Research, University of Cambridge, UK

  • Agilent Technologies
  • Bruker Corporation
  • Human Metabolome Technologies
  • LECO Corporation
  • Shimadzu Corporation
  • Thermo Fisher Scientific, Inc.
  • Waters Corporation